The Patent Finder

Somerset Therapeutics, LLC

40 patents currently held · Updated Nov 20, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
May 2035
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 11, 2027
    The maintenance fee for Buffer-free, stable ophthalmological compositions of ketorolac and phenylephrine and applications thereof (US 11,696,910) comes due Jan 11, 2027. Unpaid by Jul 12, 2027, it lapses early.
  • 2 fees due Apr 17 to 24, 2027 · next Apr 17
  • 1 fee due Jun 26, 2027
    The maintenance fee for Methods of efficiently reducing intraocular pressure (US 11,850,249) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
  • 3 fees due Jul 2 to 30, 2027 · next Jul 2
  • 1 fee due Oct 30, 2027
    The maintenance fee for Low pH pilocarpine and brimonidine compound formulations and related methods (US 11,969,410) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 22, 2026
  • 1 term has ended since Aug 22, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,707,174Aqueous ophthalmic solution of olopatadine
In force (reinstated)
 · USPTO record
In force (reinstated)USPTO record
US 12,023,315Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
In force
 · USPTO record
In forceUSPTO record
US 11,400,100Effective benzalkonium chloride-free bimatoprost ophthalmic compositions
In force
 · USPTO record
In forceUSPTO record
US 11,564,931Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
In force
 · USPTO record
In forceUSPTO record
US 11,786,538Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
In force
 · USPTO record
In forceUSPTO record
US 11,517,522Aprepitant ready-to-use injection emulsion compositions
In force
 · USPTO record
In forceUSPTO record
US 11,298,368Efficient tobramycin compound conjugate compositions
In force
 · USPTO record
In forceUSPTO record
US 11,395,831Combination products of tobramycin compounds and dexameihasone compounds
In force
 · USPTO record
In forceUSPTO record
US 11,478,491Tobramycin compound-copolymer conjugates and derivative compositions
In force
 · USPTO record
In forceUSPTO record
US 11,478,492Tobramycin compound conjugate formulations
In force
 · USPTO record
In forceUSPTO record
10 of 40 patents shown.
Pro members see all 40.
Pro members: see all 40 patents
Also on record, not counted in the 40: 3 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 14 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited